J&J falls despite a beat-and-raise quarter. Why we’re raising our price target anyways
Johnson & Johnson shares fell Tuesday despite a mostly strong second-quarter earnings report and an increase to its…
Johnson & Johnson has a chance to show it’s more than just a rotation winner
Johnson & Johnson shares have showed signs of life ahead of earnings. For the stock to keep running,…
J&J CEO sends a clear message on the obesity drug boom
Johnson & Johnson (JNJ) just told Wall Street it will sit out the most lucrative drug race of…